MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
7.85
+0.10
+1.29%
After Hours: 7.85 0 0.00% 19:37 07/19 EDT
OPEN
7.78
PREV CLOSE
7.75
HIGH
7.90
LOW
7.67
VOLUME
1.17M
TURNOVER
0
52 WEEK HIGH
11.31
52 WEEK LOW
1.995
MARKET CAP
1.22B
P/E (TTM)
-7.1801
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 2d ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. Has agreed to grant inducement awards to its newly appointed Senior Vice President, Chief of Staff, Chad Clatterbaugh. The company is a biopharmaceutical company. Ocular is developing therapies for wet age-related macular degeneration, diabetic retinopathy and other diseases of the eye.
Barchart · 3d ago
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler
TipRanks · 4d ago
Weekly Report: what happened at OCUL last week (0708-0712)?
Weekly Report · 6d ago
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
TipRanks · 07/12 10:37
Ocular Therapeutix To Present Late-Breaking Abstract Of HELIOS Study At 42nd ASRS Annual Scientific Meeting
Ocular Therapeutix, Inc. Is a biopharmaceutical company developing innovative therapies for wet age-related macular degeneration, diabetic retinopathy and other diseases of the eye. A late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI will be presented at the ASRS Annual Scientific Meeting.
Benzinga · 07/10 12:11
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
Ocular Therapeutix, Inc. Is a biopharmaceutical company committed to enhancing people's vision and quality of life. The company is developing innovative therapies for wet age-related macular degeneration and diabetic retinopathy. A late-breaking abstract will be presented at the American Society of Retina Specialists.
Barchart · 07/10 07:00
Weekly Report: what happened at OCUL last week (0701-0705)?
Weekly Report · 07/08 10:57
More
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.